Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
Rapid

Intrauterine contraception

Essential points for quick revision.

Saved on this device
!
Pain, pregnancy or perforation needs urgent assessment

Severe pain, collapse, bleeding, fever or a positive pregnancy test with an IUD can indicate ectopic pregnancy, perforation or pelvic infection.

Action: Assess observations and pregnancy location urgently, examine with consent, use transvaginal ultrasound and hCG as indicated, treat sepsis promptly and obtain gynaecology advice before blind traction or uterine instrumentation.

Synopsis

Select, insert and monitor copper and levonorgestrel intrauterine contraception using exact device dose, indication, duration and urgent pregnancy or perforation pathways.

  • A copper IUD prevents fertilisation without hormone and can also provide emergency contraception; LNG-IUDs thicken cervical mucus and suppress endometrium, with dose-specific bleeding benefits and durations.
  • For contraception, any 52mg LNG-IUD inserted before age 45 is supported for up to eight years; when inserted at age 45 or older it can remain for contraception until age 55.
  • The eight-year 52mg extension is contraceptive only. Follow current product or professional duration for heavy menstrual bleeding and five-year endometrial protection with oestrogen therapy; 19.5mg and 13.5mg devices retain five- and three-year contraceptive durations.

Key red flags

Any pregnancy with IUC in situ requires prompt location assessment; pain, shoulder-tip pain, syncope or bleeding raises immediate ectopic concern.

Severe insertion pain, inability to sound normally, absent threads or a device seen outside the cavity suggests perforation or malposition; do not attempt blind removal.

Fever, pelvic tenderness and discharge after insertion require infection assessment, while the background STI risk must be distinguished from the device itself.

A 52mg LNG-IUD has an eight-year contraceptive duration when inserted before age 45, but that extension does not apply to heavy menstrual bleeding or endometrial protection.

Postpartum insertion is UKMEC 1 from birth to 48 hours, category 3 from 48 hours to under four weeks, category 1 from four weeks and category 4 with postpartum sepsis.

Possible expulsion

New thread length, feeling plastic, return of bleeding or pregnancy symptoms can indicate partial or complete expulsion.

Possible perforation

Severe insertion pain, absent threads or an extrauterine device on imaging requires localisation before any removal attempt.

Pregnancy with IUC

Positive testing, pain or bleeding requires urgent ectopic assessment and specialist management of the device.

Pelvic infection

Fever, lower abdominal pain, purulent discharge or cervical excitation needs prompt STI and sepsis assessment.

Investigation priorities

01
Pregnancy assessmentFirst step

Reasonably exclude pregnancy before insertion and identify pregnancy when symptoms or device failure occur.

Management branches

Insertion pathwayMatch device to goal and uterus

A patient chooses IUC for contraception, bleeding treatment or emergency use.

  1. Record pregnancy risk, STI context, uterine anatomy, bleeding goals, contraindications and the exact device dose and indication.
  2. Explain analgesia, insertion steps, perforation, expulsion, bleeding change, infection symptoms and product-specific duration.

Key medicines

Copper intrauterine deviceInsert the selected licensed copper device once into the uterine cavity and retain for its product duration, emergency indication or supported age-at-insertion extension.May increase bleeding or pain; exclude pregnancy, assess infection and uterine distortion, and respond urgently to perforation or ectopic symptoms.
52mg levonorgestrel intrauterine deviceInsert once; use for up to eight years for contraception when inserted before age 45, or until age 55 if inserted at age 45 or older, while applying shorter indication-specific treatment durations.Do not transfer the eight-year contraceptive duration to endometrial protection or every bleeding indication; record product, dose, age and purpose.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 13 Sept 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom